LUD 5466.4 CIP - JEL/NDH

If the examiner feels that claims 89-91 are not allowable, this is her prerogative; however, the rules <u>are clear</u>: If the examiner changes position, following an indicia of allowability, then the prosecution must be re-opened.

This has already happened once. See applicants response of August 21. If it happens again, the Group Director will be involved in further discussions. An explanation is called for not a complete lack of response, as was the case with respect to claim 93, and applicants prior remarks.

AMENDMENT

Please amend this application as follows:

IN THE CLAIM

Cancel claims 6-8, 11-13, 16-54, 61-81 and 85-87, without prejudice.

	Add claims 89	9-95:
	Claim 89:	An isolated polypeptide which binds to an MHC-Class II DR53
	J	molecule, wherein said polypeptide consists of an amino acid sequence
	/1	set forth in SEQ ID NO: 8, 9, 10, 11, 12 or 13.
W_{I}	Claim 96:	The isolated polypeptide of claim 29,3the amino acid sequence of which
•		is set forth at SEQ ID NO: 8, 9 or 10.
	Claim 91.5	A composition comprising the isolated polypeptide of claim 89, and at
	<i>(</i> .	least one adjuvant. 5
	Claim 92:	The composition of claim 91, wherein said polypeptide is SEQ ID NO: 8,
	÷	9 or 10.
	Claim 93:	A composition comprising a mixture of at least two of the polypeptides
	ď	defined by SEQ ID NOS: 8, 9 and 10.
	Claim 94:	The composition of claim 93, further comprising an adjuvant.
	Claim 95: 7	A composition comprising:
		(i) a first polypeptide, the amino acid sequence of which consists of
		the amino acid sequence set forth in SEQ ID NO: 7, and
		(ii) at least one additional polypeptide, the amino acid sequence of
		which consists of the amino acid sequence set forth in SEQ ID
		NO: 8, 9 or 10.